HIV and accelerated atheroprogression: Role of antiretroviral therapy

Antonio Di Biagio, Valerio Del Bono, Raffaella Rosso, Claudio Viscoli

Research output: Contribution to journalArticlepeer-review


The introduction of effective and potent treatments for human immunodeficiency virus (HIV) infection resulted in prolonged survival and better quality of life of HIV-infected patients. However, the longer survival and the anti-HIV medication side effects caused the emergence of new clinical issues, such as the increase in cardiovascular risk, favored by multiple factors, partly related to HIV infection itself, partly to the anti-HIV molecules. HIV infection itself may affect cardiovascular risk through chronic inflammation induced by uncontrolled viral replication, whereas long-term antiretroviral therapy may increase the cardiovascular risk through several mechanisms. Thus, due to the multiple and conflicting causes of cardiovascular disorders in HIV-infected patients, clinicians should take into consideration all modifiable risk factors, in order to implement an effective prevention of this clinical issue.

Original languageEnglish
Pages (from-to)88-96
Number of pages9
JournalCurrent Pharmaceutical Biotechnology
Issue number1
Publication statusPublished - Jan 2012


  • AIDS
  • Antiretroviral therapy
  • Atherosclerosis
  • Cardiovascular risk
  • Endothelium
  • HIV infection
  • Lipids

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Biotechnology


Dive into the research topics of 'HIV and accelerated atheroprogression: Role of antiretroviral therapy'. Together they form a unique fingerprint.

Cite this